KLHL36: A Potential Drug Target and Biomarker (G79786)

Target Name: KLHL36

NCBI ID: G79786

KLHL36

KLHL36: A Potential Drug Target and Biomarker

Kallikrein-related peptidases (KLHPs) are a family of enzymes that belong to the serine proteases superfamily. These peptides have been implicated in various physiological processes in the body, including tissue repair, inflammation, and metabolism. One of the KLHPs, KLHL36, has been identified as a potential drug target and biomarker for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

KLHL36 is a 29-kDa protein that is expressed in various tissues, including the brain, heart, liver, and pancreas. It is a potent serine proteases that is involved in the degradation of various peptides, including extracellular matrix (ECM) components, growth factors, and neurotransmitters. KLHL36 has been shown to play a crucial role in the regulation of cell survival and growth, and its dysfunction has been implicated in the development of various diseases.

One of the most significant findings related to KLHL36 is its involvement in cancer. Many studies have shown that KLHL36 is expressed in various types of cancer, including breast, lung, and colorectal cancer. Additionally, these studies have demonstrated that KLHL36 is involved in the regulation of cell cycle progression and the maintenance of cancer cell survival. Therefore, KLHL36 has emerged as a potential drug target for cancer treatment.

In addition to its involvement in cancer, KLHL36 has also been shown to be involved in autoimmune disorders. autoimmune disorders are a group of diseases in which the immune system attacks the body's own tissues, leading to inflammation and damage. KLHL36 has been shown to play a role in the regulation of immune cell function and the development of autoimmune disorders.

KLHL36 has also been shown to be involved in neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to contribute to the underlying causes of these diseases. KLHL36 has been shown to be involved in the regulation of neurofibrillary tangles and the degradation of neurotransmitters, which may be important in the development and progression of neurodegenerative diseases.

In conclusion, KLHL36 is a protein that has been shown to be involved in various physiological processes in the body, including cancer, autoimmune disorders, and neurodegenerative diseases. Its potential as a drug target and biomarker makes it an attractive target for research and development of new treatments for these conditions. Further studies are needed to fully understand the role of KLHL36 in these processes and to develop effective treatments.

Protein Name: Kelch Like Family Member 36

Functions: Probable substrate-specific adapter of an E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins

The "KLHL36 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLHL36 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets